Cite

HARVARD Citation

    Sanchez, L. et al. (2021). Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Therapeutic advances in hematology. p. . [Online]. 
  
Back to record